PropertyValue
?:abstract
  • INTRODUCTION: As coronavirus disease 2019 (COVID-19) outbreak globally, repurposing approved drugs is emerging as important therapeutic options. Danoprevir boosted by ritonavir (Ganovo) is a potent hepatitis C virus (HCV) protease (NS3/4A) inhibitor, which was approved and marketed in China since 2018 to treat chronic hepatitis C patients. METHODS: This is an open-label, single arm study evaluating the effects of danoprevir boosted by ritonavir on treatment naïve and experienced COVID-19 patients for the first time. Patients received danoprevir boosted by ritonavir (100 mg/100 mg, twice per day). The primary endpoint was the rate of composite adverse outcomes and efficacy was also evaluated. RESULTS: The data showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients. No patient had composite adverse outcomes during this study. After initiation of danoprevir/ritonavir treatment, the first negative reverse real-time PCR (RT-PCR) test occurred at a median of 2 days, ranging from 1 to 8 days, and the obvious absorption in CT scans occurred at a median 3 days, ranging from 2 to 4 days. After 4 to 12-day treatment of danoprevir boosted by ritonavir, all enrolled 11 patients were discharged from the hospital. CONCLUSION: Our findings suggest that repurposing danoprevir for COVID-19 is a promising therapeutic option.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1097/md.0000000000023357
?:journal
  • Medicine_(Baltimore)
?:license
  • cc-by-nc
?:pdf_json_files
  • document_parses/pdf_json/4d43b6781467e61cfd533f76f3c6a9adcc3f78e2.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7710192.xml.json
?:pmcid
?:pmid
?:pmid
  • 33235105.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients
?:type
?:year
  • 2020-11-25

Metadata

Anon_0  
expand all